AW
NBIX icon

Avion Wealth’s Neurocrine Biosciences NBIX Stock Holding History

Avion Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Buy
17
+9
+113% +$1.33K ﹤0.01% 1097
2026
Q1 		$1K Hold
8
– – ﹤0.01% 1092
2025
Q4 		$1K Sell
8
-4
-33% -$579 ﹤0.01% 1084
2025
Q3 		$1K Buy
12
+4
+50% +$542 ﹤0.01% 1060
2025
Q2 		$1K Sell
8
-8
-50% -$917 ﹤0.01% 1016
2025
Q1 		$2K Hold
16
– – ﹤0.01% 749
2024
Q4 		$2K Sell
16
-2
-11% -$247 ﹤0.01% 746
2024
Q3 		$2K Sell
18
-8
-31% -$1.1K ﹤0.01% 703
2024
Q2 		$3K Buy
26
+4
+18% +$549 ﹤0.01% 565
2024
Q1 		$4K Buy
22
+12
+120% +$1.64K ﹤0.01% 512
2023
Q4 		$1K Sell
10
-10
-50% -$1.15K ﹤0.01% 887
2023
Q3 		$2K Buy
+20
New +$2.11K ﹤0.01% 504

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Avion Wealth's NBIX Position: Q2 2026 in Review

Avion Wealth increased its Neurocrine Biosciences (NBIX) stake by 113% in Q2 2026, buying an estimated $1.33K and bringing the position to 17 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1097.

Avion Wealth first reported a position in NBIX in Q3 2023 and has held it in 12 quarters since. The position peaked at $4K in Q1 2024. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Avion Wealth held 17 shares of Neurocrine Biosciences worth $2K as of Q2 2026.
  • Avion Wealth bought 9 Neurocrine Biosciences shares in Q2 2026, an estimated $1.33K.
  • Neurocrine Biosciences made up ﹤0.01% of Avion Wealth's portfolio in Q2 2026, its #1097 holding.
  • Avion Wealth first reported a position in Neurocrine Biosciences in Q3 2023 and has held it in 12 quarters since.
  • Avion Wealth's Neurocrine Biosciences position peaked at $4K in Q1 2024.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Avion Wealth's 13F filing for Q2 2026, filed 31 Jul 2026.